Skip to main content
SpringerLink
Log in
Book cover

Intraventricular Conduction Disturbances pp 338–380Cite as

Effect of Antiarrhythmic Drugs on Intraven­tricular Conduction

  • Chapter

  • 52 Accesses

Part of the book series: Developments in Cardiovascular Medicine ((DICM,volume 12))

Abstract

Classification of antiarrhythmic drugs has always been a controversial subject. In recent years it has become increasingly so with so many new compounds appear­ing on the pharmacological horizon. Furthermore there is no complete under­standing of either the electropharmacology of the antiarrhythmic agent or the mechanisms engendering various cardiac arrhythmias, despite the recent contri­butions by investigators using ultramicroelectrode and His bundle recording.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Vaughan Williams EM: The classification of antiarrhythmic drugs. In: Symposium on cardiac arrhythmias, Sandol E, Fleusted-Jensen E, Olesen Kh. Sodertalje, Sweden: AB Astra 1970, p 449

    Google Scholar 

  2. Singh BN, Hauswirth O: Comparative mechanism of action of antiarrhythmic drugs. Am Heart J 87: 367, 1974

    PubMed  CAS  Google Scholar 

  3. Dreifus LS, Ogawa S: Quality of the ideal antiarrhythmic drug. Am J Cardiol 39: 466, 1977

    PubMed  CAS  Google Scholar 

  4. Ferrari M, Maragno I, Melacini P: Una classificazione dei farmaci antiaritmici quale indicazione alla terapia clinica. In: Le nuove frontiere delle aritmie, Furlanello F, Disertori M. Lanzetta L. Padua: Piccin, 1977, p 185

    Google Scholar 

  5. Touboul P, Attalah G, Gressard A, Michelon G, Chatelain MY, Delahaye JP: Effets électrophysiologiques des agents antiarythmiques chez l’homme. Tentative de classification. Arch Mal Coeur 72: 72, 1979

    PubMed  CAS  Google Scholar 

  6. Hoffman BF: The action of quinidine and procaine amide on single fibers of dog ventricle and specialized conduction system. Ann Bras Ciencias 29: 365, 1957

    Google Scholar 

  7. West TC, Amory DW: Single fiber recording of the effects of quinidine at the atrial and pacemaker sites in the isolated right atrium of the rabbit. J Pharmacol Exp Ther 130: 183, 1960

    PubMed  CAS  Google Scholar 

  8. Gettes LS, Surawicz B, Shive JC: Effect of high K, low K on QRS duration and ventricular action potential. Am J Physiol 203: 1135, 1962

    PubMed  CAS  Google Scholar 

  9. Watanabe Y, Dreifus LS, Likoff WL: Electrophysiological antagonism and synergism of potassium and antiarrhythmic agents. Am J Cardiol 12: 702, 1963

    PubMed  CAS  Google Scholar 

  10. Conn HI Jr, Luchi RJ: Some cellular and metabolic considerations relating to the action of quinidine as a prototype antiarrhythmic agent. Am J Med 37: 685, 1964

    PubMed  CAS  Google Scholar 

  11. Wallace AG, Cline RE, Sealy WC, Young WG, Troyer WG: Electrophysiological effects of quinidine. Circ Res 19: 960, 1966

    PubMed  CAS  Google Scholar 

  12. Wald RB, Vaxman MB, Downar E: The effect of antiarrhythmic drugs on depressed conduction and unidirectional block in sheep Purkinje fibers. Circ Res 46: 612, 1980

    PubMed  CAS  Google Scholar 

  13. Heissenbuttel RH, Bigger JT Jr: The effects of oral quinidine on intraventricular conduction in man: correlation of plasma quinidine with changes in QRS duration. Am Heart J 80: 453, 1970

    PubMed  CAS  Google Scholar 

  14. Moe GK, Abildskov JA: Antiarrhythmic drugs. In: The pharmacologic basis of therapeutics, 4th edn, Goodman LS, Gilman A. New York: Macmillan, 1970, p 709

    Google Scholar 

  15. Damato AN, Lau SH: The clinical value of the electrogram of the conduction system. Progr Cardiovasc Dis 13: 119, 1970

    CAS  Google Scholar 

  16. Josephson ME, Seides SF, Batsford WP, Wisfogel GM, Akhtar M, Caracta AR, Lau SH, Damato AN: The electrophysiological effects of intramuscular quinidine on the atrioventricular conducting system in man. Am Heart J 87: 55, 1974

    PubMed  CAS  Google Scholar 

  17. Watanabe Y, Dreifus L: Interactions of quinidine and potassium on atrioventricular transmission. Circ Res 20: 434, 1967

    PubMed  CAS  Google Scholar 

  18. Mirro MJ, Watanabe AM, Bailey JC: Electrophysiological effects of disopyramide and quinidine on guinea pig atria and canine cardiac Purkinje fibers. Dependence on underlying cholinergie tone. Circ Res 46: 660, 1980

    PubMed  CAS  Google Scholar 

  19. Sokolow M, Perloff DB: The clinical pharmacology and use of quinidine in heart disease. Progr Cardiovasc Dis 3: 316, 1961

    CAS  Google Scholar 

  20. Marriott HJL: Rational approach to quinidine therapy. Mod Concepts Cardiovasc Dis 31: 745, 1962

    PubMed  CAS  Google Scholar 

  21. Kock-Weser J: Antiarrhythmic prophylaxis in ambulatory patients with coronary heart disease. Arch Intern Med 129: 763, 1972

    Google Scholar 

  22. Giardina EGV, Heissenbuttel RH, Bigger JT Jr: Intermittent intravenous procaine amide to treat ventricular arrhythmias. Ann Intern Med 78: 183, 1973

    PubMed  CAS  Google Scholar 

  23. Woske H, Belford J, Fasier FN: The effect of procainamide on excitability, refractoriness and conduction in the mammalian heart. J Pharmacol Exp Ther 107: 134, 1953

    PubMed  CAS  Google Scholar 

  24. Weidman S: Effects of calcium ions and local anesthetic on electrical properties of Purkinje fibers. J Physiol 129: 568, 1955

    Google Scholar 

  25. Hoffman BF: The possible mode of action of antiarrhythmic agents. In: The myocardial cell, Briller S, Coon H. Philadelphia: University of Pennsylvania Press, 1966, p 251

    Google Scholar 

  26. Helfant RH, Scherlag BJ, Damato AN: The electrophysiological properties of diphenylhydantoin sodium as compared to procainamide in the normal and digitalis intoxicated dog. Circulation 36: 108, 1867

    Google Scholar 

  27. Rosen KM, Lisi KR, Berkowitz WS: The effect of procaineamide on atrioventricular and intraventricular conduction in man. Circulation (Abstr) 39: Suppl III: 111–173, 1969

    Google Scholar 

  28. Josephson ME, Caracta AR, Ricciutti MA, Lau SH, Damato AD: Electrophysiologic properties of procainamide in man. Am J Cardiol 33: 596, 1974

    PubMed  CAS  Google Scholar 

  29. Reddy CP, Damato AN, Akatar M, Dhatt M, Gomes JAC, Calon AH: Effect of procainamide on reentry within the His-Purkinje system in man. Am J Cardiol 40: 957, 1977

    PubMed  CAS  Google Scholar 

  30. Ogunkeiv JB, Damato AN, Akatar M, Reddy CP, Carata AR, Lau SH: Electro-physiologic effects of procainamide in subtherapeutic to therapeutic doses on human atrioventricular conduction system. Am J Cardiol 37: 724, 1976

    Google Scholar 

  31. Scheinman MM, Weiss AN, Shafton E, Benowitz N, Rowland M: Electrophysiologic effects of procaineamide in patients with intraventricular conduction delay. Circulation 49: 522, 1974

    PubMed  CAS  Google Scholar 

  32. Wedd AM, Blair HA, Warner RS: The action of procaine amide on the heart. Am Heart J 42: 399, 1951

    PubMed  CAS  Google Scholar 

  33. Siddiqui S, Siddiqui RH: The alkaloids of Rauwolfia serpentinaBenth. Part I. J Ind Chem Soc 9: 539, 1932

    CAS  Google Scholar 

  34. Arora RB, Madan BR: Antiarrhythmics VI. Ajmaline and serpentine in experimental cardiac arrhythmias. J Pharmacol Exp Ther 117: 62, 1956

    PubMed  CAS  Google Scholar 

  35. Kleinsorge H: Klinische Untersuchungen über die Wirkungsweise des Rauwolfia-alkaloids Ajmaline bei Herzrhythmusstörungen insbesondere der Extrasistolie. Med Klin 54: 409, 1959

    CAS  Google Scholar 

  36. Puech P, Latour H, Hertault J, Grolleau R: L’ajmaline injectable dans les tachycardies paroxystiques et le syndrome WPW. Comparaison avec la procainamide. Arch Mal Coeur 57: 897, 1964

    PubMed  CAS  Google Scholar 

  37. Bazika V, Lang TW, Pappelbaum S, Corday E: Ajmalin, a rauwolfia alkaloid for the treatment of digitoxis arrhythmias. Am J Cardiol 17: 227, 1966

    PubMed  CAS  Google Scholar 

  38. Bianchi C, Beccari E: L’ajmalina nella terapia delle aritmie cardiache. Sperimentazione policentrica pianificata. Min Med 57: 1273, 1966

    Google Scholar 

  39. Farinelli A, Zanardi A, Degli Atti B, Longhini C, Alvisi A: Rilievi clinici sull’impiego dell’ajmalina in talune aritmie accessuali. Min Cardioangiol 16: 1047, 1968

    CAS  Google Scholar 

  40. Wellens HJJ, Durrer D: Effect of procaine amide, quinidine and ajmaline in the Wolff-Parkinson-White syndrome. Circulation 50: 114, 1974

    PubMed  CAS  Google Scholar 

  41. Kleinsorge A. Gaida P: Quantities and rates of excretion of the Rauwolfiaalkaloid ajmaline following different methods of administration. Arzneim Forsch 11: 1100, 1961

    CAS  Google Scholar 

  42. Kleinsorge H. Gaida P: Behaviour of the serum level after intravenous injection of ajmaline. Klin Wschr 40: 149, 1962

    PubMed  CAS  Google Scholar 

  43. Petter A, Zipf K: Zur antifibrillaren Herzwirkung von Ajmaline, Brom-Ajmalin, Chinidin und Novocainamid. Arch Exp Pharmacol 243: 519, 1962

    CAS  Google Scholar 

  44. Capra C: Sull’attività antiaritmica di alcuni derivati dell’ajmalina. Il Farmaco 19: 865, 1964

    CAS  Google Scholar 

  45. Vorgatti E, Pascucci E, Mavulis A, Magnani B: Risultati clinici preliminari sull’attività antiaritmica di un derivato acetilato dell’ajmalina: la dicloroacetilajmalina. Boll Soc Ital Card 8: 494, 1963

    Google Scholar 

  46. Botti G, Visioli O, Barbaresi F, Lazzari GB: Primi risultati sperimentali sull’attività antiaritmica di un derivato acetilato dell’ajmalina: la dicloroacetilajmalina. Boll Soc It Card 11: 135, 1966

    CAS  Google Scholar 

  47. Cocour V, Enesco R, Sirbulesco R, Pompilian P. La di-monocloroacetilajmalina nel trattamento delle alterazioni del ritmo cardiaco. Min Med 61: 16, 1970

    Google Scholar 

  48. Coumel P, Bouvrain Y: Pharmacodynamics and clinical results in 95 cases. In: Concepts on the mechanisms and treatment of arrhythmias, Gensini GG. New York: Futura, 1974, p 97

    Google Scholar 

  49. Pretolani E: Clinical studies on the antiarrhythmic properties of MCAA. In: Concepts on the mechanisms and treatment of arrhythmias, Gensini GG. New York: Futura, 1974, p 125

    Google Scholar 

  50. Ross P, Messina G, Giampaolo P, Cernigliaro C: Rapporto tra concentrazione plasmatica ed effetto antiaritmico della di-monocloroacetilajmalina. G Ital Cardiol 4: 444, 1974

    Google Scholar 

  51. Obayashi K, Mandel WJ: Electrophysiological effects of ajmaline in isolated cardiac tissue. Cardiovasc Res 10: 20, 1976

    PubMed  CAS  Google Scholar 

  52. De Azevedo IM, Dreifus LS, Watanabe Y: Electrophysiologic effects of new ester of ajmaline 17-monochloroacetyl ajmaline hydrochloride (MCAA). Europ J Cardiol 2: 321, 1975

    Google Scholar 

  53. Piwonka RW, Canniff PC, Healey JF: Electrophysiological effects of a new antiarrhythmic agent in cardiac tissue. In: Concepts on the mechanisms and treatment of arrhythmias, Genzini GG. New York: Futura, 1974, p 219

    Google Scholar 

  54. Knippel M, Cadel A, Mazzini C, Figini A, Rovelli F: Effetti dell’ajmaline e della dimonocloroacetilajmalina sulla conduzione atrioventricolare ed intraventricolare nell’uomo. G Ital Cardiol 1: 321, 1971

    PubMed  CAS  Google Scholar 

  55. Camerini F, Baldi N, Gori P, Martinoli E: L’ajmalina nello studio prognostico dei blocchi bifascicolari. E’ possibile valutare il rischio di evoluzione verso il blocco totale? G Ital Cardiol 3: 880, 1973

    PubMed  CAS  Google Scholar 

  56. Jacovella G, Santini M, Dini P, Alliegro A, Floris B, Masini V: Effect of 17-monochloroacetylajmaline (MCAA) upon conduction and excitability of the human heart. In: Concepts on the mechanisms and treatment of arrhythmias, Gensini GG. New York: Futura, 1974, p 151

    Google Scholar 

  57. Meilhac B, Le Pailleur C, Heulin A, Vacheron A, Guise L, Di Matteo J: Intérêt de la stimulation auriculaire et des épreuves pharmaco-dynamiques dans le diagnostic des syncopes à électrocardiogramme normal. Arch Mal Coeur 67: 775, 1974

    PubMed  CAS  Google Scholar 

  58. Morena H, Chaltiel G, Denis B, Rossignol B, Machecourt J, Martin Noel P: Effets dromotropes des associations médicamenteuses. Premiers resultats sur l’association deslanoside-ajmaline. Arch Mal Coeur 70: 749, 1977

    PubMed  CAS  Google Scholar 

  59. Alboni P, Malacarne C, Pedroni P: Effetti elettrofisiologici dell’ajmalina sul sistema di conduzione nell’uomo. G Ital Cardiol 8: 752, 1978

    PubMed  CAS  Google Scholar 

  60. Guerot CL, Valere PE, Castillo-Fenoy A, Coste A, Morice MC: Action comparée de l’ajmaline et du chloracetylajmaline sur la conduction auriculo-ventriculaire de l’homme. Coeur Med Int 14: 129, 1975

    CAS  Google Scholar 

  61. Seipel L, Both A, Breithardt G, Gleichman V, Loogen F: Action of antiarrhythmic drugs on His bundle electrocardiogram and sinus node function. Acta Cardiol (Suppl) 18: 251, 1974

    Google Scholar 

  62. Shigenobu K, Kasuya J, Ishiko J, Fukada J: The actions of N-propyl Ajmaline on experimental arrhythmias and electrophysiological properties of the heart. Chem i’harm Bull 22: 2329, 1974

    CAS  Google Scholar 

  63. Sekiya A, Vaughan Williams EM: A comparison of the antifibrillatory actions and effects on intracellular cardiac potentials of Pronethalol, Disopyramide and Quinidine. Br J Pharmacol 21: 473, 1963

    CAS  Google Scholar 

  64. Colonna D, Sorouche M, Tep T, Calisti G: Le traitement des troubles du rythme cardiaque par la disopyramide. Coeur Med Int 7: 455, 1968

    CAS  Google Scholar 

  65. Granier J: La disopyramide nel trattamento delle alterazioni ritmiche. Min Med 61: 3718, 1970

    CAS  Google Scholar 

  66. Mathur PP: Cardiovascular effects of a newer antiarrhythmic agent, disopyramide phosphate. Am Heart J 84: 764, 1972

    PubMed  CAS  Google Scholar 

  67. Hulting J, Rosenhamer G: Antiarrhythmic and haemodynamic effects of intravenous and oral disopyramide in patients with ventricular arrhythmia. J Int Med Res (Suppl I ), 4: 9, 1976

    Google Scholar 

  68. Mizgala HF, Huvell PR: Acute termination of cardiac arrhythmias with intravenous disopyramide. J Int Med Res (Suppl I ) 4: 82, 1976

    Google Scholar 

  69. Ranney RE, Dean RR, Karim A, Radzialowski FM: Disopyramide phosphate: phar-macokinetic and pharmacologic relationship of a new antiarrhythmic agent. Arch Int Pharmacodyn Ther 191: 162, 1971

    PubMed  CAS  Google Scholar 

  70. Yen BK, Sung P, Scherlag BJ: Effects of disopyramide on electrophysiological and mechanical properties of the heart. J Pharm Sciences 62: 1924, 1973

    Google Scholar 

  71. Edwards IR, Martin JF, Ward JW: The effect of disopyramide on in vivo measurement of monophasic action potential in canine heart muscle. J Intern Med Res (Suppl I ): 4: 26, 1976

    Google Scholar 

  72. Levites R, Anderson GJ: Electrophysiological effects of disopyramide phosphate during experimental myocardial ischemia. Am Heart J 98, 339, 1979

    PubMed  CAS  Google Scholar 

  73. Josephson ME, Caracta AR, Lau S, Gallagher JJ, Damato AN: Electrophysiological evaluation of disopyramide in man. Am Heart J 86: 771, 1973

    PubMed  CAS  Google Scholar 

  74. Befeler B, Castellanos A Jr, Wells DE, Vagueiro MC, Yen BK: Electrophysiological effects of the antiarrhythmic agent disopyramide phosphate. Am J Cardiol 35: 282, 1975

    PubMed  CAS  Google Scholar 

  75. Spurrell RAJ, Thorburn CW, Camm J, Sowton E, Deuchar DC: Effects of disopyramide on electrophysiological properties of specialized conduction system in man and on accessory atrioventricular pathway in Wolff-Parkinson-White syndrome. Br heart J 37: 861, 1975

    PubMed  CAS  Google Scholar 

  76. Marrott PK, Ruttley MSI, Winterbottom JT, Muit JR: A study of the acute electrophysiological and cardiovascular action of disopyramide in man. Europ J Cardiol 4: 303, 1976

    CAS  Google Scholar 

  77. Birkhead JS, Vaughan Williams EM: Dual effect of disopyramide on atrial and atrioventricular conduction and refractory periods. Br Heart J 39: 657, 1977

    PubMed  CAS  Google Scholar 

  78. Desai JM, Scheinman M, Peters R, O’Young J: Electrophysiological effects of disopyramide in patients with bundle branch block. Circulation 59: 215, 1979

    PubMed  CAS  Google Scholar 

  79. Bigger JF, Bassett AL, Hoffman BF: Electrophysiological effects of diphenylhydantoine in canine Purkinje fibers. Circ Res 22: 221, 1968

    PubMed  CAS  Google Scholar 

  80. Bigger JT, Mandel WJ: Effects of lidocaine on the electrophysiological properties of ventricular muscle and Purkinje fibers. Circ Res 22: 221, 1968

    PubMed  CAS  Google Scholar 

  81. Davis LD, Temte JV: Electrophysiological actions of lidocaine on canine ventricular muscle and Purkinje fibers. Circ Res 24: 639, 1969

    PubMed  CAS  Google Scholar 

  82. Mandel WS, Bigger JT: Effect of lidocaine on sino-atrial node and atrial fibers. Am J Cardiol 25: 113, 1970

    Google Scholar 

  83. Southworth JL, McKusick VA, Peirce EC, Rawson FL Jr: Ventricular fibrillation precipitated by cardiac catheterization. JAMA 143: 717, 1950

    CAS  Google Scholar 

  84. Cotoi S, Luca C: Effetti della lidocaina nelle aritmie sopraventricolari. G Ital Cardiol 6: 433, 1976

    PubMed  CAS  Google Scholar 

  85. Hoffman BF, Bigger JT Jr: Antiarrhythmic drugs. In: Drill’s pharmacology in medicine, 4th edn Palma JR. New York: McGraw-Hill, 1971, p 824

    Google Scholar 

  86. Benowits N, Forsyth RP, Melmon KL, Rowland M: Lidocaine disposition kinetics in monkey and man. I. Prediction by a perfusion model. Clin Pharmacol Ther 16: 87, 1974

    Google Scholar 

  87. Sung CY, Truant AP: The physiological disposition of lidocaine and its comparison in some respects with procaine. J Pharmacol Exp Ther 112: 432, 1954

    PubMed  CAS  Google Scholar 

  88. Scott DB, Jerson PJ, Vellani CW, Julian DG: Plasma lignocaine levels after intravenous and intramuscular injection. Lancet 1: 41, 1970

    PubMed  CAS  Google Scholar 

  89. Alboni P: La lidocaina intramuscolare nel trattamento delle aritmie. G Ital Cardiol 1: 581, 1971

    PubMed  CAS  Google Scholar 

  90. Bellet S, Roman L, Kostis JB, Fleischmann D: Intramuscular lidocaine in the therapy of ventricular arrhythmias. Am J Cardiol 27: 291, 1971

    PubMed  CAS  Google Scholar 

  91. Fehmers MCO, Dunning AJ: Intramuscularly and orally administered lidocaine in the treatment of ventricular arrhythmias in acute myocardial infarction. Am J Cardiol 29: 514, 1972

    PubMed  CAS  Google Scholar 

  92. Sarnoff SJ: Plasma levels of lidocaine after intramuscular administration. Am J Cardiol 29: 520, 1972

    PubMed  Google Scholar 

  93. Rossi P, Lombardi M, Lotto A, Puddu V: La lidocaina per via intramuscolare nella prevenzione delle complicazioni e della mortalità nell’infarto miocardico acuto. Studio a doppio cieco di 246 casi. G Ital Cardiol 6: 220, 1976

    PubMed  CAS  Google Scholar 

  94. Bigger JT Jr, Mandel WJ: Effect of lidocaine on canine Purkinje fibers and at the ventricular muscle-Purkinje fiber junction. J Pharmacol Exp Ther 172: 239, 1970

    PubMed  CAS  Google Scholar 

  95. Bigger JT Jr, Mandel WJ: Effect of lidocaine on transmembrane potentials of ventricular muscle and Purkinje fibers. J Clin Invest 49: 63, 1970

    PubMed  CAS  Google Scholar 

  96. Sasyniuk BI, Kus T: Comparison of the effects of lidocaine on electrophysiological properties of normal Purkinje fibers and those surviving acute myocardial infarction. Fed Proc (Abstr) 33: 476, 1974

    Google Scholar 

  97. El-Sherif N, Scherlag BJ, Lazzara R: Re-entrant ventricular arrhythmias in the late myocardial infarction period. IV. Mechanism of action of lidocaine. Circulation 56: 395, 1977

    PubMed  CAS  Google Scholar 

  98. Kupersmith J, Antam EM, Hoffman BF: In vivo electrophysiological effects of lidocaine in canine acute myocardial infarction. Circ Res 36: 84, 1975

    PubMed  CAS  Google Scholar 

  99. Rosen MR, Merker C, Pippenger CE: Effects of clinically relevant plasma lidocaine concentrations on electrophysiologic properties of canine Purkinje fibers. Circulation 48 (Suppl) IV: 209, 1973

    Google Scholar 

  100. Rosen MR, Hoffman BF, Wit AL: Electrophysiology and pharmacology of cardiac arrhythmias. V. Cardiac antiarrhythmic effects of lidocaine. Am Heart J 89: 526, 1975

    PubMed  CAS  Google Scholar 

  101. Rosen MR, Merker C, Pippenger CE: The effects of lidocaine on the canine ECG and electrophysiologic properties of Purkinje fibers. Am Heart J 91: 191, 1976

    PubMed  CAS  Google Scholar 

  102. Rosen KM, Lau SH, Weiss MB, Damato AN: The effect of lidocaine on atrioventricular and intraventricular conduction in man. Am J Cardiol 25: 1, 1970

    PubMed  CAS  Google Scholar 

  103. Kunkel F, Rowland M, Scheinman MM: The electrophysiological effects of lidocaine in patients with intraventricular conduction defects. Circulation 49: 894, 1974

    PubMed  CAS  Google Scholar 

  104. Bekheit S, Murtagh JG, Fletcher E: Effect of lignocaine on conducting system of human heart. Br Heart J 35: 305, 1973

    PubMed  CAS  Google Scholar 

  105. Gupta PK, Lichstein E, Chadda KD: Lidocaine-induced heart block in patients with bundle branch block. Am J Cardiol 39: 550, 1974

    Google Scholar 

  106. Roos JC, Dunning A: Effects of lidocaine on impulse formation and conduction defects in man. Am Heart J 89: 686, 1975

    PubMed  CAS  Google Scholar 

  107. Josephson ME, Caracta AR, Gallagher JJ, Damato AN: Effects of lidocaine on refractory periods in man. Am Heart J 84: 1778, 1972

    Google Scholar 

  108. Gerstenblith G, Scherlag BJ, Hope RR, Lazzara R: Effect of lidocaine on conduction in the ischemic His-Purkinje system in dog. Am J Cardiol 42: 587, 1978

    PubMed  CAS  Google Scholar 

  109. Harris AS, Kodernot RH: Effects of diphenylhydantoin sodium (Dilantin) sodium and phenobarbital sodium upon ectopic ventricular tachycardia in acute myocardial infarction. Am J Physiol 163: 505, 1950

    PubMed  CAS  Google Scholar 

  110. Leonard WA: The use of diphenylhydantoin (Dilantin) sodium in the treatment of ventricular tachycardia. Arch Inter Med 101: 714, 1958

    Google Scholar 

  111. Mercer EN, Osborn JA: The current status of diphenylhydantoin in heart disease. Ann Inter Med 67: 1084, 1967

    CAS  Google Scholar 

  112. Eddy JD, Singh SP: Treatment of cardiac arrhythmias with phenytoin. Br Heart J 4: 270, 1969

    CAS  Google Scholar 

  113. Bigger JT Jr, Schmidt DH, Kutt H: Relationship between the plasma level of diphenylhydantoin sodium and its cardiac antiarrhythmic effects. Circulation 38: 363, 1968

    PubMed  Google Scholar 

  114. Kutt H: Biochemical and genetic factors regulating Dilantin metabolism in man. Ann NY Acad Sci 179: 704, 1971

    CAS  Google Scholar 

  115. Maynert EW: The metabolic fate of diphenylhydantoin in the dog, rat and man. J Pharmacol Exp Ther 130: 275, 1960

    PubMed  CAS  Google Scholar 

  116. Bigger JT Jr, Bassett AL, Hoffman BF: Electrophysiological effects of diphenylhydantoin on canine Purkinje fibers. Circ Res 22: 221, 1968

    PubMed  CAS  Google Scholar 

  117. Bassett AL, Bigger JT Jr, Hoffman BF: Prospective action of diphenylhydantoin on canine Purkinje fibers during hypoxia. J Pharmacol Exp Ther 173: 336, 1970

    PubMed  CAS  Google Scholar 

  118. Helfant RH, Scherlag BJ, Damato AN: The electrophysiological properties of diphenylhydantoin sodium as compared to procaine amide in the normal and digitalis intoxicated heart. Circulation 36: 108, 1967

    PubMed  CAS  Google Scholar 

  119. Rosati RA, Alexander JA, Schall SF, Wallace AG: Influence of diphenylhydantoin on electrophysiological properties of the canine heart. Circ Res 21: 757, 1967

    PubMed  CAS  Google Scholar 

  120. Damato AN, Berkowitz WD, Patton RD, Lau SH: The effect of diphenylhydantoin on atrioventricular and intraventricular conduction in man. Am Heart J 79: 51, 1970

    PubMed  CAS  Google Scholar 

  121. Caracta AR, Damato AN, Josephson ME, Riccuittu MA, Gallagher JJ, Lau SH: Electrophysiologic properties of diphenylhydantoin. Circulation 47: 1234, 1973

    PubMed  CAS  Google Scholar 

  122. Bissett JK, De Soyza NDB, Kane JJ, Murphy ML: Improved intraventricular conduction of premature beats after diohenylhydantoin. Am J Cardiol 33: 493, 1974

    PubMed  CAS  Google Scholar 

  123. Helfant RH, Scherlag BJ, Damato AN: Use of diphenylhydantoin sodium to dissociate the effects of procainamide on automaticity and conductions in the normal and arrhythmic heart. Am J Cardiol 20: 280, 1967

    Google Scholar 

  124. Haiat R, Chapelle M, Benaim R: Effect of diphenylhydantoin on intraventricular conduction disturbance: report of a case. J Electrocardiol 5: 197, 1972

    PubMed  CAS  Google Scholar 

  125. Evans GH, Shand DG: Disposition of propranolol. IV. Independent variation in steady state circulating drug concentration and half-life as a result of plasma drug binding in man Clin Pharmacol Ther 14: 494, 1973

    CAS  Google Scholar 

  126. Nies AS, Whand DG: Clinical pharmacology of propranolol. Circulation 52: 6, 1975

    PubMed  CAS  Google Scholar 

  127. Shand DG, Nuckolls EM, Oates JA: Plasma propranolol levels in adults, with observations in four children. Clin Pharmacol Ther 11: 112, 1970

    PubMed  CAS  Google Scholar 

  128. Walle T, Gaffney TE: Propranolol metabolism in man and dog: mass spectrometric identification of six new metabolites. J Pharmacol Exp Ther 182: 83, 1972

    PubMed  CAS  Google Scholar 

  129. With AL, Hoffman BE, Rosen MR: Electrophysiology and pharmacology of cardiac arrhythmias. IX. Cardiac electrophysiologic effects of beta adrenergic receptor stimulation and blockade. Part C. Am Heart J 90: 795, 1975

    Google Scholar 

  130. Davis LD, Temte JV: Effects of propranolol on the transmembrane potentials of ventricular muscle and Purkinje fibers in the dog. Circ Res 23: 661, 1968

    Google Scholar 

  131. Coltart DJ, Meldrum SJ: The effect of racemic propranolol, dextropropranolol and racemic practolol on the human and canine cardiac transmembrane action potential. Arch Int Pharmacodyn 192: 188, 1971

    PubMed  CAS  Google Scholar 

  132. Strauss HC, Bigger JT Jr, Hoffman BF: electrophysiological and beta-receptor blocking effects of MJ 1999 om dog and rabbit cardiac tissue. Circ Res 26: 661, 1970

    PubMed  CAS  Google Scholar 

  133. Kumakura S, Somani P: The effects of LB-46, a ß-adrenoceptor blocking drug on isolated normal and ouabain intoxicated Purkinje fibers of the dog. Europ J Pharmacol 25: 335, 1974

    CAS  Google Scholar 

  134. Wu CH, Narashashi T: Mechanism of action of propranolol on squid axon membranes. J Pharmacol Exp Ther 184: 155, 1973

    PubMed  CAS  Google Scholar 

  135. Berkowitz WD, Wit AL, Lau SH, Steiner C, Damato AH: Effects of propranolol on cardiac conduction. Circulation 40: 855, 1969

    CAS  Google Scholar 

  136. Smithen CS, Balcon R, Sowton E: Use of His potentials to assess changes in atrioventricular conduction produced by a series of beta-adrenergic blocking agents. Br Heart J 33: 955, 1971

    PubMed  CAS  Google Scholar 

  137. Seides SF, Josephson ME, Batsford WP, Weisfogel GM, Lau SH, Damato AN: The electrophysiology of propanolol in man. Am Heart J 88: 733, 1974

    PubMed  CAS  Google Scholar 

  138. Seipel L, Both A, Breithardt G, Gleichmann U, Loogen F: Action of antiarrhythmic drugs on His bundle electrogram and sinus node function. Acta Cardiol, Suppl XVIII, 251, 1974

    Google Scholar 

  139. Dini P, Santini M, Di Mascolo R, Milazzotto F, Jacovella G: Effetti elettrofisiologici del pindololo in pazienti con disturbi della eccito-conduzione. VI Congr. Naz ANMCO Rome: Pozzi, 1975, p 322

    Google Scholar 

  140. Alboni P, Malacarne C, Tomasi AM, Masoni A: Effetti del tolamololo sulla eccitoconduzione nell’uomo. G Ital Cardiol 7: 862, 1977

    PubMed  CAS  Google Scholar 

  141. Di Biase M, Guglielmi R, Scarcia A, Chiddo A, Rizzon P: Electrophysiologic properties of intravenous oxprenolol in man. J Electrocardiol 10: 267, 1977

    PubMed  Google Scholar 

  142. Rizzon P, Di Biase M, Chiddo A, Mastrangelo D, Sorgente L: Electrophysiologic properties of intravenous metoprolol in man. Br Heart J 40: 650, 1978

    PubMed  CAS  Google Scholar 

  143. Di Biase M, Favale S, Rizzon P: Electrophysiologic properties of intravenous tenormine in man. Europ J Cardiol 9: 333, 1979

    Google Scholar 

  144. Charlier R: Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoreceptors. Br J Pharmacol 39: 668, 1970

    PubMed  CAS  Google Scholar 

  145. Coumel P, Bouvrain Y: Etude clinique des effets pharmacodynamiques et antiarythmiques de l’amiodarone. J Agrèges 6: 69, 1973

    Google Scholar 

  146. Fauchier JP, Brochier M, Raynaud R: Etude clinique des effets anti-arythmiques ventriculaires de l’amiodarone (orale et injectable). Ann Cardiol Angeiol 22: 427, 1973

    CAS  Google Scholar 

  147. Rosenbaum MB, Chiale PA, Halpern MS, Nau GJ, Przybylski J, Levi RJ, Lazzari JO, Elizari MV: Clinical efficacy of Amiodarone as an antiarrhythmic agent. Am J Cardiol 38: 934, 1976

    PubMed  CAS  Google Scholar 

  148. Broekhuysen J, Laurel R, Sion R: Etude comparée du transit et du métabolisme de l’amiodarone chez diverses espèces animales et chez l’homme. Arch Inter Pharmacodyn Thér 177: 340, 1969

    CAS  Google Scholar 

  149. Singh BN, Vaughan Williams EM: The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol 39: 657, 1970

    PubMed  CAS  Google Scholar 

  150. Cabasson J, Puech P, Melle JM, Guimond G, Bachy C, Sassine A: Analyse des effets électrophysiologiques de l’amiodarone par l’enregistrement simultane des potentiels d’action monophasiques et du faisceau de His. Arch Mal Coeur 69: 691, 1976

    PubMed  CAS  Google Scholar 

  151. Olsson SB, Brorson L, Varnauskas E: Class 3 antiarrhythmic action in man. Observations from monoplasic action potential recordings and amiodarone treatment. Br Heart J 35: 1255, 1973

    PubMed  CAS  Google Scholar 

  152. Curry PVC: Fundamentals of arrhythmias: modern methods of investigation. In: Cardiac arrythmias. The modern electrophysiological approach, Krikler D, Goodwin JF. London: WB Saunders, 1975, p. 39

    Google Scholar 

  153. Disertori M, Molinis G, Vergara G, Bettini R, Furlanello F: Effetti dell’amiodarone sulla conduzione atrio-ventricolare e ventricolo-atriale nella sindrome di Wolff-Parkinson-White. G. Ital Cardiol 6: 792, 1976

    CAS  Google Scholar 

  154. Touboul H, Huerta F, Porte J, Delahaye JP: Bases électrophysiologiques de l’action antiarythmique de l’amiodarone chez l’homme. Arch Mal Coeur 69: 845, 1976

    PubMed  CAS  Google Scholar 

  155. Wellens HJJ, Lie KI, Bar FW, Wesdorp JC, Dohmen HJ, Duren Dr, Durrer D: Effect of amiodarone in the Woll-Parkinson-White syndrome. Am J Cardiol 38: 189, 1976

    PubMed  CAS  Google Scholar 

  156. Waleffe A, Bruninx P, Kulbertus HE: Effects of amiodarone studied by programmed electrical stimulation of the heart in patients with paroxysmal re-entrant supraventriular tachycardia. J Electrocardiol 11: 253, 1978

    PubMed  CAS  Google Scholar 

  157. Bacaner M: Bretylium tosylate for suppression of induced ventricular fibrillation. Am J Cardiol 17: 528, 1966

    PubMed  CAS  Google Scholar 

  158. Terry G, Vellani CW, Higgins MR, Doig A: Bretylium toxylate in treatment of refractory ventricular arrhythmias complicating myocardial infarction. Br Heart J 32: 21, 1070

    Google Scholar 

  159. Dhurandhar RW, Teasdale SJ, Mahon WA: Bretylium tosylate in the management of refractory ventricular fibrillation. Can Med Ass J 105: 161, 1971

    PubMed  CAS  Google Scholar 

  160. Berstein JG, Koch-Weser J: Effectiveness of bretylium tosylate against refractory ventricular arrhythmias. Circulation 45: 1024, 1972

    Google Scholar 

  161. Wit AL, Steiner C, Damato AM: Electrophysiological effects of bretylium tosylate on single fibers of the canine specialized conduction system and ventricle. J Pharmacol Exp Ther 173: 344, 1970

    PubMed  CAS  Google Scholar 

  162. Bigger JT, Jaffe CC: The effect of bretylium tosylate on the electrophysiological properties of ventricular muscle and Purkinje fibers. Am J Cardiol 27: 82, 1971

    PubMed  CAS  Google Scholar 

  163. Haas, H, Hartfelder G: a-Isopropyl-â-[N-methyl-N-homoveratril)-6-aminopropyl]3,4-dimethoxyphenyl-acetonitril, eine Substanz mit Coronargefässerweiternden Eigenschaften. Arzneimittel Forsch 12: 549, 1962

    CAS  Google Scholar 

  164. Schamroth L, Krikler DM, Garrett C: Immediate effects of intravenous verapamil in cardiac arrhythmias. Br Med J 1: 660, 1972

    PubMed  CAS  Google Scholar 

  165. Krikler D: Verapamil in cardiology. Europ J Cardiol 2: 10, 1974

    Google Scholar 

  166. Spurrell RAJ, Krikler M, Sowton E: Concealed bypass of the A-V node in patients with paroxismal supraventricular tachycardia revealed by intracardiac electrical stimulation and intravenous verapamil. Am J Cardiol 33: 590, 1974

    PubMed  CAS  Google Scholar 

  167. Rosen MR, Wit AL, Hoffman BF: Electrophysiology and pharmacology of cardiac arrhythmias. VI. Cardiac effects of Verapamil. Am Heart J 89: 665, 1975

    PubMed  CAS  Google Scholar 

  168. Belz GG, Bender F: Therapie der Herzrhythmusstörungen mit Verapamil. Stuttgart: Gustav Fischer, 1974

    Google Scholar 

  169. Fleckenstein A: Specific inhibitors and promotors of calcium action in the excitation-contraction coupling of heart muscle and their role in the prevention or production of myocardial lesions. In: Calcium and the heart, Harris P, Opie LH. New York: Academic Press, 1971, p 135

    Google Scholar 

  170. Kohlhardt M, Baver B, Krause H, Fleckenstein A: New selective inhibitors of the transmembrane Ca conductivity in mammalian myocardial fibers. Experientia 15: 288, 1972

    Google Scholar 

  171. Shigenobu K, Schneider JA, Sperelakis N: Verapamil blockade of slow Na + and Ca++ responses in myocardial cells. J Pharmacol Exp Ther 190: 280, 1974

    PubMed  CAS  Google Scholar 

  172. Rosen MR, Ilvento JP, Gelband H, Merker C: Effects of verapamil on electrophysiologic properties of canine cardiac Purkinje fibers. J Pharmacol Exp Ther 189: 414, 1974

    PubMed  CAS  Google Scholar 

  173. Zipes DP, Besch HR, Watanabe AM: Role of the slow current in cardiac electrophysiology. Circulation 51: 761, 1975

    PubMed  CAS  Google Scholar 

  174. Dershm GH, Han J: Effects of Verapamil on action potentials of Purkinje fibers. J Electrocardiol 13: 67, 1980

    Google Scholar 

  175. El-Sherif N, Lazzara R: Reentrant ventricular arrhythmias in the late myocardial infarction period. 7. Effect of Verapamil and D-600 and the role of the slow channel. Circulation 60: 605, 1979

    PubMed  CAS  Google Scholar 

  176. Fazzini PF, Marchi F, Pucci P: Azione antiaritmica del Verapamil nell’infarto miocardico acuto. Considerazioni sul possibile meccanismo d’azione. G Ital Cardiol 7: 940, 1977

    PubMed  CAS  Google Scholar 

  177. Elharrar V, Gaum WE, Zipes DP: Effect of drugs on conduction delay and incidence of ventricular arrhythmias induced by acute coronary occlusion in dogs. Am J Cardiol 39: 544, 1977

    PubMed  CAS  Google Scholar 

  178. Husaini MH, Kvasnicka J, Rysen L, Holmberg S: Action of Verapamil in sinus node, atrioventricular, and intraventricular conduction. Br Heart J 35: 734, 1973

    PubMed  CAS  Google Scholar 

  179. Rizzon P. Di Biase M, Calabrese P, Brindicci G, Chiddo A: Electrophysiologic evaluation of intravenous Verapamil in man. Europ J Cardiol 6: 179, 1977

    CAS  Google Scholar 

  180. Hoffman BF: Effects of digitalis on electrical activity of cardiac membranes. In: Basic and clinical pharmacology of digitalis, Marks BH, Weissler AM. Springfield: Charles C. Thomas, 1972, p 118

    Google Scholar 

  181. Kassebaum DC: Electrophysiological effects of strophantin on the heart. J Pharmacol Exp Ther 140: 329, 1963

    Google Scholar 

  182. Hashimoto K, Moe GK: Transient depolarizations induced by acetylstrophanthidin in specialized tissue of dog atrium and ventricle. Cire Res 32: 618, 1973

    CAS  Google Scholar 

  183. Davies LD: Effect of changes in cycle length on diastolic depolarization produced by ouabain in canine Purkinje fibers. Circ Res 32: 206, 1973

    Google Scholar 

  184. Ferrier GR, Saunders JH, Mendez C: A cellular mechanism for the generation of ventricular arrhythmias by acetylstrophanthidin. Circ Res 32: 600, 1973

    PubMed  CAS  Google Scholar 

  185. Hogan PM, Wittenberg SM, Klocke FJ: Relationship of stimulation frequency to automaticity in the canine Purkinje fiber during ouabain administration. Circ Res 32: 377, 1973

    PubMed  CAS  Google Scholar 

  186. Rosen MR, Gelband H, Merker C, Hoffman BF: Mechanisms of digitalis toxicity: effects of ouabain on phase 4 of canine Purkinje fiber transmembrane potentials. Circulation 47: 681, 1973

    PubMed  CAS  Google Scholar 

  187. Damato AN, Lau SH: Clinical value of the electrocardiogram of the conducting system. Progr Cardiovasc Dis 13: 119, 1970

    CAS  Google Scholar 

  188. Puech P, Grolleau R: L’enregistrement endocavitaire des potentiels du tissu de conduction. Rev Prat 22: 1207, 1972

    PubMed  CAS  Google Scholar 

  189. Przybyla AC: Effects of digoxine on atrio-ventricular conduction pattern in man. Am J Cardiol 33: 344, 1974

    PubMed  CAS  Google Scholar 

  190. Gomes JA, Dhatt MS, Akhtar M, Carambas CR, Rubenson DS, Damato AN: Effects of digitalis on ventricular myocardial and His-Purkinje refractoriness and reentry in man. Am J Cardiol 42: 931, 1978

    PubMed  CAS  Google Scholar 

  191. Gomes JA, Damato AN, Bobb G, Lau S: The effect of digitalis on refractoriness of the intact canine His-Pukinje system. Circulation 58: 284, 1978

    PubMed  CAS  Google Scholar 

  192. Gaultier M, Fournier E, Efthymiou ML, Freaville JP, Jouannot P, Dentan M: Intoxications digitaliques aiguës (70 observations). Bull Soc Med Hop 119: 247, 1968

    CAS  Google Scholar 

  193. Ollagnier J: Digitaliques et conduction cardiaque coeur. Med Int 17: 537, 1978

    CAS  Google Scholar 

  194. Akhtar M, Damato AN, Caracta AR, Batsford WP, Josephson ME, Lau SH: Electrophysiologic effects of atropine on atrioventricular conduction studied by His bundle electrogram. Am J Cardiol 33: 333, 1974

    PubMed  CAS  Google Scholar 

  195. Hoffman BF, Singer DH: Appraisal of the effects of catecholamines on cardiac electrical activity. In: New adrenergic blocking drugs: their pharmacological, biochemical and clinical actions, Moran N. Ann NY Acad Sci 139: 914, 1967

    Google Scholar 

  196. Giotti A, Ledda F, Mannaioni PF: Effects of noradrenaline and isoprenaline in combination with a and ß-receptor blocking substances on the action potential of cardiac Purkinje fibers. J Physiol 229: 99, 1973

    PubMed  CAS  Google Scholar 

  197. Wit AL, Hoffman BF, Rosen RR: Electrophysiology and pharmacology of cardiac arrhythmias. IX. Cardiac electrophysiologic effects of beta adrenergic receptor stimulation and blockade. Part A. Am Heart J 90: 521, 1975

    PubMed  CAS  Google Scholar 

  198. Trautwein W, Schmidt RZ: Zur Membranwirkung des Adrenalin an der Herzmuskelfaser. Pflügers Arch 271: 715, 1960

    CAS  Google Scholar 

  199. Cannom DS, Rider A, Stinson EB, Harrison DC: Electrophysiologic studies in the denervated transplanted heart. II. Response to norepinephrine, isoproterenol and propranolol. Am J Cardiol 36: 859, 1975

    PubMed  CAS  Google Scholar 

  200. Vargas G, Akhtar M, Damato AN: Electrophysiologic effects of isoproterenol on cardiac conduction system in man. Am Heart J 90: 25, 1975

    PubMed  CAS  Google Scholar 

  201. Masoni A, Alboni P, Malacarne C, Codeca’ L: Effects of Dobutamine on electrophysiological properties of the specialized conduction system in man. J Electrocardiol 12: 361, 1979

    PubMed  CAS  Google Scholar 

  202. Dhingra RC, Winslow E, Pouget J, Rahimtoola S, Rosen KM: The effect of isoproterenol on atrioventricular and intraventricular conduction. Am Heart J 90: 25, 1975

    Google Scholar 

  203. Masini G, Gherardi C, Dianda R, Cuccu E: Effetti della dopamina sulla conduzione atrio-ventricolare ed intraventricolare. G ltal Cardiol 3: 545, 1973

    CAS  Google Scholar 

  204. Kesteloot H, Van Mieghem W, De Geest H: Aprindine (AC 1802). A new antiarrhythmic drug. Acta Cardiol 28: 145, 1973

    PubMed  CAS  Google Scholar 

  205. Fasola AF, Carmichael R: The pharmacology and clinical evaluation of aprindine, a new antiarrhythmic agent. Acta Cardiol (Suppl) 18: 317, 1974

    Google Scholar 

  206. Fasola AF, Noble RJ, Zipes DP: Treatment of recurrent ventricular tachycardia and fibrillation with aprindine. Am J Cardiol 39: 903, 1977

    PubMed  CAS  Google Scholar 

  207. Pouleur H, Chaudron JM, Reyns P: Effects of disopyramide and aprindine on arrhythmias after acute myocardial infarction. Europ J Cardiol 5: 397, 1977

    CAS  Google Scholar 

  208. Murphy PJ: Metabolic pathways of aprindine. Acta Cardiol (Suppl) 18: 131, 1976

    Google Scholar 

  209. Delcroix C, Martin L, Van Durme JP, Kesteloot H, Hagemeijer F, Mbuyamba P, Deblecker M: Model for exchange kinetics of aprindine in man after single and multiple doses. Acta Cardiol (Suppl) 18: 177, 1974

    Google Scholar 

  210. Verdonck F, Vereecke J, Vleugels A: Electrophysiological effects of aprindine on isolated heart preparations. Europ J Pharm 26: 338, 1974

    CAS  Google Scholar 

  211. Steinberg MI, Greenspan K: Intracellular electrophysiological alterations in canine cardiac conducting tissue induced by aprindine and lignocaine. Cardiovasc Res 10: 236, 1976

    PubMed  CAS  Google Scholar 

  212. Greene HL, Reid PR, Schaeffer AH: Prolongation of cardiac conduction times by intravenous aprindine in man. Am J Cardiol 42: 1002, 1978

    PubMed  CAS  Google Scholar 

  213. Zipes DP, Troup PJ: New antiarrhythmic agents. Amiodarone, Aprindine, Disopyramide, Ethmozim, Mexiletine, Tocainide, Verapamil. Am J Cardiol 41: 1005, 1978

    PubMed  CAS  Google Scholar 

  214. Vergara G, Disertori M, Molinis G, Mama G, Antonini L, Del Favero A, Stefenelli C, Furlanello F: Studio degli effetti elettrofisiologici dell’aprindine nell’uomo con particolare riferimento alla sindrome da preeccitazione ventricolare. G Ital Cardiol 9: 597, 1979

    PubMed  CAS  Google Scholar 

  215. Kesteloot H, Van de Werf F, Marchandise B, Sluyts R: Influence of moxaprindine treatment on ventricular arrhythmias occurring during maximal exercise stress testing. Acta Cardiol 34: 301, 1979

    PubMed  CAS  Google Scholar 

  216. Waleffe A, Mary-Rabine L, Kulbertus HE: Study of moxaprindine with programmed electrical stimulation of the heart in patients with reentrant tachyarrhythmias. Am J Cardiol 45: 640, 1980

    PubMed  CAS  Google Scholar 

  217. Beani L: Profilo farmacologico di un nuovo antiaritmico: la bunaftide. Boll Soc It Card 17: 1279, 1972

    CAS  Google Scholar 

  218. Lotto A, Lomanto B, Bossi M: Prime esperienze nell’impiego clinico di un nuovo antiaritmico: la bunaftide. Cardiol Prat 23: 123, 1972

    PubMed  CAS  Google Scholar 

  219. Masini G, Cuccu E, Zanetti L: Sull’impiego della bunaftide nel trattamento ambulatoriale di alcuni disturbi del ritmo cardiaco. Boll Soc It Card 17: 1173, 1972

    CAS  Google Scholar 

  220. Rossi P, Carcano G, Rognoni G, Cernigliaro C, Calcaterra G: Correlazione fra concentrazioni plasmatiche ed effetto antiaritmico della bunaftide. G Ital Cardiol 6: 1048, 1976

    PubMed  CAS  Google Scholar 

  221. Ferroni A, Monticelli G: Electrophysiological aspects of the action of bunaphtine on single cardiac muscle fibres. Pharmacol Res 5: 151, 1973

    CAS  Google Scholar 

  222. Bonatti V, Finardi A, Cabasson J, Botti G: L’effetto della bunaftide sui potenziali di azione monofasici del miocardio atriale e ventricolare destro nell’uomo. Nota preliminare. G Ital Cardiol 6: 440, 1976

    PubMed  CAS  Google Scholar 

  223. Bonatti V, Finardi A, Cabasson J, Botti G: Studio sul meccanismo d’azione della bunaftide mediante registrazione dei potenziali d’azione monofasici del miocardio nell’uomo. Nota conclusiva. G Ital Cardiol 6: 1378, 1976

    PubMed  CAS  Google Scholar 

  224. Scibilla G, Bonatti V, Pavarani A, Tagliavini S, Botti G: Effetto sul fascio di His di una nuova sostanza antiaritmica, la bunaftide. Cardiol Prat 24: 79, 1973

    Google Scholar 

  225. Grazi S, Romano S, Bonazzi O, Pozzoni L, Cavoretto D, Gardumi L, Sardella F: Effetti di un nuovo antiaritmico, la bunaftide, sulla conduzione intraatriale, atrioventricolare ed intraventricolare dello stimolo. Cardiol Prat 25: 213, 1974

    PubMed  CAS  Google Scholar 

  226. Byrne JE, Gomoll AW: Antiarrhythmic activity of MJ 9067. Fed Proc (Abstr) 32: 812, 1973

    Google Scholar 

  227. Byrne JE, Gomoll AW: Antiarrhythmic properties of MJ 9067 in acute animal models. J Pharmacol Exp Ther 200: 147, 1977

    PubMed  CAS  Google Scholar 

  228. Gibson JK, Somani PF, Bassett A: Effect of MJ 9067 on transmembrane potentials of canine cardiac Purkinje fibers (Abstr). Pharmacology 18: 169, 1976

    Google Scholar 

  229. Sami M, Mason JW, Oh G, Harrison DC: Canine electrophysiology of Encainide, a new antiarrhythmic drug. Am J Cardiol 43: 1149, 1979

    PubMed  CAS  Google Scholar 

  230. Sami M, Mason JW, Peters F, Harrison DC: Clinical electrophysiologic effects of Encainide, a newly developed antiarrhythmic agent. Am J Cardiol 44: 526, 1979

    PubMed  CAS  Google Scholar 

  231. Kaverina NV, Senova DP, Vikhlyayev YI, Ul’yanova OV: Antiarrhythmic properties of ethmozine. Farmako Toksikol 33: 693, 1970

    CAS  Google Scholar 

  232. Votchal BY, Lozinskiy LG: Efficacy of a new antiarrhythmic drug, ethmozim. Klin Med (Mosk) 10: 16, 1971

    Google Scholar 

  233. Senova ZP, L’Vov MV: Mechanism of the antiarrhythmic effect of ethmozim Farmakol Toksikol 36: 703, 1973

    CAS  Google Scholar 

  234. Morganroth J, Pealman AS, Dunkam WB, Horowitz LN, Josephson ME, Michelson EL: Ethmozim: a new antiarrhythmic agent developed in the USSR. Efficacy and tolerance. Am Heart J 98: 621, 1979

    PubMed  CAS  Google Scholar 

  235. Podrid PJ, Lyakishev A, Lown B, Mazur N: Ethmozim, a new antiarrhythmic drug for suppression of ventricular premature complexes. Circulation 61: 450, 1980

    PubMed  CAS  Google Scholar 

  236. Danilo P, Langman WB, Rosen MR, Hoffman BF: Effects of phenothiazine analog, EN 131, on ventricular arrhythmias in the dog. Europ J Pharmacol 45: 127, 1977

    CAS  Google Scholar 

  237. Ruffy R, Rozenshtraukh L, Elharrar V, Zipes DP: Cardiac electrophysiologic properties of ethmozim. Clin Res (Abstr) 25: 557, 1977

    Google Scholar 

  238. Campbell NPS, Kelly JG, Shanks RG, Chaturvedi NC, Strong JE, Partridge JF: Mexiletine (Ko 1173) in the management of ventricular arrhythmias. Lancet 2: 404, 1973

    PubMed  CAS  Google Scholar 

  239. Talbot RG, Nimmo J, Julian DG, Clark RA, Nielson JMM, Prescott LF: Treatment of ventricular arrhythmias with mexiletine (Ko 1173). Lancet 2: 399, 1973

    PubMed  CAS  Google Scholar 

  240. Heger JJ, Nattel S, Rinkenberger RL, Zipes DP: Mexiletine therapy in 15 patients with drug-resistant ventricular tachycardia. Am J Cardiol 45: 627, 1980

    PubMed  CAS  Google Scholar 

  241. Prescott LF, Clements JD, Pottage A: Absorption, distribution and elimination of mexiletine. Postgrad Med J (Suppl) 53: 50, 1977

    CAS  Google Scholar 

  242. Weld FM, Bigger JT, Swistel D, Bordiuk J, Lau YH: Electrophysiological effects of mexiletine (Kö 1173) on ovine cardiac Purkinje fibers. (In preparation)

    Google Scholar 

  243. Roos JC, Paalman ACA, Dunning AJ: Electrophysiological effects of mexiletine in man. Br Heart J 38: 1261, 1976

    Google Scholar 

  244. McComish M, Kitson D, Robinson CC, Jewitt DE: Clinical electrophysiological effects of mexiletine. Postgrad Med J 53 (Suppl I): 85, 1977

    PubMed  Google Scholar 

  245. Beck OA, Kramer KD, Wolff R, Muller A, Hochrein H: Propafenon, ein neues Antiarrhythmikum zur Therapie tachycarder und extrasystolischer Herzrhythmusstörungen. Med Klin 70, 95: 1975

    PubMed  CAS  Google Scholar 

  246. Ador E, Heeger I: Propafenon, ein neues Antiarrhythmikum. Dtsch Med Wschr 101: 1318, 1976

    Google Scholar 

  247. Kock R: Zur Propafenon-wirkung bei ventrikularer Arrhythmie. In: Fortschritte in der Pharmakotherapie von Herzrhythmusstörungen 1, Hochrein H, Hapke Hi, Beck OA. Internationales Propafenon-Symposium. Stuttgart: Gustav Fischer, 1977, p 84

    Google Scholar 

  248. Fazzini PF, Marchi F, Santoro GM, Pucci P, Zambaldi G: Profilo di un nuovo antiaritmico: il proprafenone. Contributo casistico in terapia clinica. (In preparation)

    Google Scholar 

  249. Keller K, Meyer-Estorf G, Beck OA, Hochrein H: Correlation between serum concentration and pharmacological effect of atrioventricular conduction time of the antiarrhythmic drug. Europ J Pharmacol 13: 17, 1978

    CAS  Google Scholar 

  250. Bergamann M, Bolte HD: Elektrophysiologische Untersuchungen mit Propafenon in myokardialen Einzelfasern. In: Fortschritte in der Pharmakotherapie von Herzrhythmusstörungen I, Hochrein H, Hapke HJ, Beck OA. Internationales Propafenon-Symposium. Suttgart: Gustav Fischer, 1977, p 84

    Google Scholar 

  251. Seipel L, Both A, Breithardt G, Loogen F: Die Wirkung neuer Antiarrhythmika (Aprindin, Propafenon, Ci 661) auf die intrakardiale Anregungsleitung und die Sinusknotenautomatik beim Menschen. (Personal communication)

    Google Scholar 

  252. McDevitt DG, Nies AS, Wilkinson GR, Smith RF, Woosley RL, Oates JA: Antiar-rhythmic effects of a lidocaine congener, tocainide, 2-amino-2, 6-propionoxylidide in man. Clin Pharmacol Ther 19: 396, 1976

    CAS  Google Scholar 

  253. Lewinter MM, Englel RE, Karliner JS: Tocainide therapy for treatment of ventricular arrhythmias: assessment with ambulatory electrocardiographic monitoring and treadmill exercice. Am J Cardiol 45: 1045, 1980

    PubMed  CAS  Google Scholar 

  254. Harrison DC, Meffin PJ, Winkle RA: Clinical pharmacokinetics of antiarrhythmic drugs. Prof Cardiovasc Dis 20: 217, 1977

    CAS  Google Scholar 

  255. Gerstenblith G, Spear JF, Moore EN: Electrophysiological effects of a new antiarrhythmic drug. Clin Res 21: 419, 1973

    Google Scholar 

  256. Anderson JL, Mason JW, Winkle RA, Meffin PJ, Fowles RE, Peters F, Harrison DC: Clinical electrophysiologic effects of tocainide. Circulation 57: 685, 1978

    PubMed  CAS  Google Scholar 

  257. Pamintuan JC, Dreifus LS, Watanabe Y: Comparative mechanism of antiarrhythmic agents. Am J Cardiol 26: 512, 1960

    Google Scholar 

  258. Watanabe Y, Dreifuss LS, Likoff W: Electrophysiologic antagonism and synergism of potassium and antiarrhythmic agents. Am J Cardiol 12: 702, 1963

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Electrophysiology Section, Division of Cardiology, Arcispedale S. Anna, Ferrara, Italy

    Paolo Alboni M.D. (Director)

Authors
  1. Paolo Alboni M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1981 Martinus Nijhoff Publishers, The Hague

About this chapter

Cite this chapter

Alboni, P. (1981). Effect of Antiarrhythmic Drugs on Intraven­tricular Conduction. In: Intraventricular Conduction Disturbances. Developments in Cardiovascular Medicine, vol 12. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-8287-1_13

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-8287-1_13

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-009-8289-5

  • Online ISBN: 978-94-009-8287-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation